Ravisankar Rajarethinam

Aug 3, 2023 | nature.com | Julia Zhao |Zaigham Khan |Xufen Yu |Ravisankar Rajarethinam |Jian Jin |Augusto Villanueva | +7 more

AbstractHepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths worldwide. β-Catenin (CTNNB1)-mutated HCC represents 30% of cases of the disease with no precision therapeutics available. Using chemical libraries derived from clinical multi-kinase inhibitor (KI) scaffolds, we screened HCC organoids to identify WNTinib, a KI with exquisite selectivity in CTNNB1-mutated human and murine models, including patient samples.